Infectious consequences of antimicrobial change from vancomycin-piperacillin/ tazobactam to vancomycin-cefepime in the prevention of AKI during orthotopic heart transplantation

原位心脏移植术中预防急性肾损伤时,抗菌药物由万古霉素-哌拉西林/他唑巴坦更换为万古霉素-头孢吡肟的感染后果

阅读:1

Abstract

BACKGROUND: Empiric antimicrobial selection in orthotopic heart transplantation (OHT) is critically important as post-operative infections are a significant cause of morbidity and mortality. While variability of antimicrobial selection exists between centers, both combinations of vancomycin and piperacillin-tazobactam (VPT) and vancomycin and cefepime (VC) are frequently used. VPT drug combination has been associated with increased risk of acute kidney injury (AKI) in multiple reports. Our study aimed to evaluate the infectious impact of changing the empiric antimicrobial selection from VPT to VC. METHODS: This was a single-center study in patients who underwent OHT at the Medical University of South Carolina (MUSC) from 2015 through 2021 (n=120). As part of a quality improvement measure, the empiric intraoperative antimicrobial therapy was transitioned from VPT (n=48) to VC (n=72) on 6/20/2019, providing a prospective setting to investigate infectious outcomes. RESULTS: A total of 10.4% of patients who received VPT had a positive culture within 30 days of OHT, compared to 9.7% of patients who received VC (p=0.781). All positive cultures were reviewed and deemed to be clinically significant infections. No significant difference in the site of culture positivity was identified between groups (p=0.487). Among patients who developed postoperative infection, there was a trend toward a longer time to infection in patients receiving VPT (median 28 days) than VC (median 14 days), p=0.08. CONCLUSIONS: Culture-positive infections within 30 days post-OHT were similar between patients receiving empiric intraoperative VPT and those receiving VC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。